Paces Ferry Wealth Advisors LLC Has $223,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Paces Ferry Wealth Advisors LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.4% in the second quarter, according to its most recent filing with the SEC. The firm owned 7,987 shares of the biopharmaceutical company’s stock after selling 640 shares during the period. Paces Ferry Wealth Advisors LLC’s holdings in Pfizer were worth $223,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Olistico Wealth LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer in the 2nd quarter valued at $29,000. Creekmur Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in shares of Pfizer in the 2nd quarter valued at $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Down 0.3 %

Shares of NYSE:PFE opened at $29.75 on Thursday. The company’s 50-day moving average price is $29.33 and its two-hundred day moving average price is $28.19. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a one year low of $25.20 and a one year high of $34.11. The stock has a market capitalization of $168.58 billion, a PE ratio of -495.75, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.67 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.65%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.